Reference : CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplant...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/6274
CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer.
English
Baron, Frédéric mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Copizza, Sandra [> > > >]
Baudoux, Etienne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >]
Jerusalem, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Fillet, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
2004
Haematologica
Ferrata Storti Foundation
89
9
1146-8
Yes (verified by ORBi)
International
0390-6078
1592-8721
Pavia
Italy
[en] Adult ; Antigens, CD34/analysis ; Antineoplastic Combined Chemotherapy Protocols/economics/therapeutic use ; Breast Neoplasms/drug therapy/economics/surgery ; Cell Count ; Combined Modality Therapy/economics ; Costs and Cost Analysis ; Drug Costs ; Fees and Charges ; Female ; Hospital Costs ; Humans ; Middle Aged ; Peripheral Blood Stem Cell Transplantation/economics ; Transplantation, Autologous/economics
[en] We assessed the effect of CD34+ cell dose on costs in breast cancer patients undergoing autologous peripheral blood stem cell (PBSC) transplantation. Mean hospitalization costs were 26,992.9+/-9582.9 for patients receiving a CD34+ cell dose <5 x 10(6) cells/kg versus 22,339.4+/- 5471.1 for those receiving >5 x 10(6) CD34+ cells/kg (p=0.0065).
http://hdl.handle.net/2268/6274

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
203.pdfPublisher postprint266.59 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.